Best Clinical Genomics Companies in Canada
The 53 best Clinical Genomics companies in Canada in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Deep Genomics.
- ResearchAndMarkets.com
- Mordor Intelligence
Ranked: Best Clinical Genomics companies in Canada
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Deep Genomics AI-powered platform for RNA biology to accelerate genetic therapy discovery 55AI top 22%Moat top 28%Funding top 29%Patents top 33% All 11 signals ▾AItop 22% Moattop 28% Fundingtop 29% Patentstop 33% Innovationtop 39% Talenttop 41% Marketbottom 49% Globalbottom 43% Techbottom 37% Growthbottom 35% Newsbottom 27% AI: Classified as an AI company · Holds AI/ML patents (G06N-family CPC) Moat: Editorial + unicorn rating 8/10 · IP moat: 92 patents rank vs industry peers · Fliar Intelligence Index 55/100 | $238M | 59 mo ago | Series C | Brendan Frey Co-Founder & Chief Innovation Officer | 2014 | WagtailPythonDjango+9 | 92 patents Patents concentrated in chemistry & materials | 6 job openings · 1 expansion |
| 2 | Repare Therapeutics Developer of targeted therapies to address the genetic alterations associated with selected tumors | $166M | 73 mo ago | Acquired | Daniel Durocher Co-Founder | 2016 | — | 161 patents Small‑molecule kinase inhibitors for cancer therapy, focusing on PLK4, ATR, MYT1 targets. | — |
| 3 | Geneseeq Providing personalised cancer treatment solutions based on patients genomic profile 55Talent top 28%Funding top 31%Moat top 40%Market bottom 49% All 5 signals ▾Talenttop 28% Fundingtop 31% Moattop 40% Marketbottom 49% Globalbottom 45% Talent: 4 named leaders on record · 4 C-suite/founder profiles curated Funding: Raised $128M across 3 rounds · 3 rounds over 12 yrs (0.2/yr) rank vs industry peers · Fliar Intelligence Index 55/100 | $128M | 78 mo ago | Series D | Xiaonan Wang Co-Founder & CTO | 2012 | — | — | — |
| 4 | Angle Developer of cancer cell capture and analysis equipment | $81M | 48 mo ago | Public | — | 1994 | WordPressMySQLPHP+23 | — | — |
| 5 | Xagenic Provider of point-of-care molecular diagnostics for infectious diseases | $59M | 132 mo ago | Series C | — | 2010 | — | 50 patents Electrochemical biosensor platforms and precision current‑mode DACs for point‑of‑care diagnostics | — |
| 6 | StageZero Life Sciences Developer of liquid biopsy test for the detection of cancer and multiple diseases | $59M | 47 mo ago | Public | James Tripp CEO | 1997 | Cart FunctionalityWeeblyMySQL+23 | — | — |
| 7 | Qvella Developer of a platform aimed to provide a more accurate and faster diagnosis of bacteria identification | $40M | 103 mo ago | Deadpooled | — | 2009 | — | 85 patents Rapid microbial diagnostics: cell separation, microcolony classification, and antibiotic susceptibility testing. | — |
| 8 | Fio Point-of-care digital diagnostic integrated with cloud information services for infectious diseases | $11M | 115 mo ago | Series B | Michael Greenberg Chairman and Chief Executive Officer | 2006 | Cart FunctionalitySquarespace CommerceSquarespace+23 | 190 patents Point‑of‑care rapid immunoassay diagnostics with biomarker analytics and cloud data integration | — |
| 9 | Med BioGene Provider of genomics-based test for the detection of early-stage lung cancer | $3M | — | Public | — | 2002 | — | — | — |
| 10 | Nimble Science Developer of personalised medicine for gut health | $3M | 39 mo ago | Seed | Sabina Bruehlmann Co-Founder & CEO | 2018 | Wix eCommerceWixSentry+13 | 16 patents Ingestible gastrointestinal sampling and targeted drug delivery devices and analysis systems | 1 partnership · 1 award |
| 11 | Mitomics Molecular diagnostics based on mitochnodrial genome | $2M | 153 mo ago | Acqui-Hired | Christopher Mitton CEO | 2010 | — | 57 patents Mitochondrial DNA deletion/ fusion biomarkers for cancer and UV‑damage diagnostics | — |
| 12 | Augurex Developer of diagnostic tests to detect autoimmune and chronic diseases | $978K | 185 mo ago | Seed | — | 2006 | WordPressMySQLPHP+26 | — | 1 award |
| 13 | Mutagentech Provider of genome-wide sequencing solutions to detect point mutations | $552K | 13 mo ago | Funding Raised | Jan Vijg Co-Founder | 2022 | — | — | — |
Top 12 Clinical Genomics companies in Canada
#1
Funding Raised · Canada · founded 2022$551.5Kraised▾
Provider of genome-wide sequencing solutions to detect point mutations. It uses range of molecular biology experiments to conduct accurate DNA sequencing on various platforms. The company has developed an error-corrected next generation sequencing platform for detecting rare somatic mutational events.
- May 2025Grant (prize money)$275.8K
- Feb 2024Grant (prize money)$275.8K
#2
Public · Surrey, British Columbia · founded 1994 · 176 employees$81.4Mraised▾
Developer of cancer cell capture and analysis equipment. The company uses liquid biopsy technology and develops Parsortix PC1 Clinical System a medical device for the capture and harvest of intact circulating tumor cells (CTCs) from metastatic breast cancer (MBC) patient blood for user-validated analysis.
- Jul 2022Post IPO$23.7M
- Oct 2020Post IPO$25.9M
- Jun 2018Post IPO$14.8M
- Jan 2018Grant (prize money)$557.5K
#3
Series C · Toronto, Ontario · founded 2014 · 105 employees$238Mraised▾
AI-powered platform for RNA biology to accelerate genetic therapy discovery. It focuses on untangling complex RNA data to identify novel targets and therapeutic candidates for genetic conditions. Its offers proprietary AI platform including the flagship model BigRNA that uses machine learning to analyze vast RNA biology data, identify therapeutic targets, and evaluate potential therapeutic candidates efficiently than traditional approaches. The technology helps accelerate early stages of drug discovery and design of RNA-based therapies.
- Jul 2021Series C$180M
- Jan 2020Series B$40M
- Sep 2017Series A$13M
- Nov 2015Seed$5M
#4
Public · Richmond Hill, Ontario · founded 1997 · 40 employees$58.8Mraised▾
StaDeveloper of liquid biopsy test for the detection of cancer and multiple diseases. The company has developed blood-based biomarker tests for the early identification of colorectal cancer known as ColonSentry which uses proprietary Sentinel principle technology. Also, it develops Aristotle mRNA-based, multi-cancer panel for screening multiple cancers.
- Aug 2022Post IPO$177K
- Mar 2022Post IPO$1.5M
- Nov 2021Post IPO$3.3M
- Dec 2020Post IPO$198.3K
#5
Acquired · Montreal, Montreal · founded 2016 · 180 employees$165.5Mraised▾
Developer of targeted therapies to address the genetic alterations associated with selected tumors. The company uses genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The company's lead candidate, PolQ, works by inhibition of Polθ thus representing a new therapeutic opportunity, particularly in tumors that carry mutations in homology-directed repair genes.
- May 2020Series B$15M
- Sep 2019Series B$82.5M
- Jun 2017Series A$68M
#6
Series D · Toronto, Ontario · founded 2012$128.4Mraised▾
Geneseeq is a health solutions company that specializes in personalized cancer care and provides treatment solutions based on the comprehensive analyses of patients’ genomic profile (RNA) using NGS techniques primarily has developed customized RNA extraction protocols for all kinds of patient sample materials, including surgical sections, core needle biopsies, FFPE samples, and ultra-low input samples.
- Dec 2019Series D$114.4M
- Jul 2017Series C—
- Jun 2016Series B$9.4M
- Aug 2014Series A$4.7M
#7
Series C · Toronto, Ontario · founded 2010 · 45 employees$59.1Mraised▾
Xagenic is developing a point-of-care platform for decentralized, rapid molecular diagnostic testing. The Xagenic X1 technology platform permits the rapid, enzyme-free detection of nucleic acids from clinical samples with automated proprietary Xagenic AuRA cartridges. The procedure involves the patient's clinical specimen to be introduced into the cartridge using a proprietary specimen collection kit and tube that snaps into the cartridge. Then, after the insertion of the cartridge into the Xagenic X1 instrument, all processes are fully automated. It is also developing assays for infectious diseases to be used with their platform.
- Jul 2015Series C$11.8M
- Jul 2014Series B$25.5M
- Dec 2013Series A$9.6M
- Jan 2012Series A$10M
#8
Seed · Calgary, Alberta · founded 2018 · 10 employees$2.7Mraised▾
Nimble Science is involved in the development of personalized medicine for gut health. It is also involved in the development of probiotic-based medicine, novel capsule, small intestine sampling tool for diagnosing, and others. The company is involved in gut microorganism sequencing and mapping and collection of the biomarker for developing personalized based medicine.
- Apr 2023Seed$2.7M
#9
Deadpooled · Richmond Hill, Ontario · founded 2009 · 101 employees$39.7Mraised▾
Developer of a platform aimed to provide a more accurate and faster diagnosis of bacteria identification. The company offers sample preparation and detection technologies to clinical microbiology; Qvella's Field Activated Sample Treatment (FAST) technology utilizes a novel electrical lysing and sample treatment technique enabling rapid detection of infectious agents in a direct blood sample.
- Dec 2017Series B$19.7M
- Jun 2017Series A—
- Oct 2015Series A$20M
#10
Series B · Toronto, Ontario · founded 2006 · 40 employees$10.7Mraised▾
Point-of-care digital diagnostic integrated with cloud information services for infectious diseases. The company has developed a portable point-of-care device capable of molecular diagnosis of multiple infectious diseases from a small biological sample. Their product, Fionet, provides a point-of-care diagnosis for infectious disease. It works with mobile devices which automatically transmits primary data to a central web portal.
- Dec 2016Series B$8.3M
- Oct 2015Series A$75.7K
- Nov 2014Series A$100K
- Oct 2014Series A$704.8K
#11
Acqui-Hired · Thunder Bay, Ontario · founded 2010$2.2Mraised▾
Mitomics, formerly Genesis Genomics, developed molecular diagnostics based on the mitochondrial genome. The company was developing assays for oncology, including skin, breast, prostrate and lung cancers. Its flagship product; Prostate Core Mitomic Test aimed to identify men at high risk of having a prostate tumor that was missed by the prostate biopsy procedure, supposedly without the need for further invasive biopsy procedures. Mitomics was acquired by MDNA Life Sciences in Nov 2014.
- Sep 2013Series A$2.1M
- Mar 2013Seed$100K
- Sep 2011Seed$51.1K
- Jun 2011Conventional Debt$25.6K
#12
Public · Vancouver, British Columbia · founded 2002 · 7 employees$3.1Mraised▾
Provider of genomics-based test for the detection of early-stage lung cancer. The company has developed GeneFx Lung (formerly LungExpress Dx), a proprietary 15 gene expression-based test for early-stage non-small-cell lung cancer (NSLC). It claims that the test provides better-informed and personalized treatment decisions to assist patients in the selection of adjuvant chemotherapy. It has a partnership with Helomics (Precision Therapeutics) for the global commercialization of GeneFx Lung.
- Post IPO$3.1M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Clinical Genomics coverage by sub-theme.
Regulatory-risk over time flat
Funding & growth over time
funding rising · growth rising
How research on Diagnostics is moving in Canada
A read on the academic research around Diagnostics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,270 Canada-affiliated papers.
- Ministry of Health175
- University of Toronto136
- McGill University111
- Princess Margaret Cancer Centre84
- University Health Network72
- Liquid biopsy8→33
- Point-of-care testing14→31
- Cancer2→18
- Biomarker2→17
- Point of care10→22
- Liquid biopsy20→97
- Biopsy5→49
- Point-of-care testing50→71
- Cancer9→28
- Biomarker6→24
- Liquid biopsy10→41
- Point-of-care testing56→67
- Biopsy5→15
- Point of care21→29
- Asymptomatic3→11
Where diagnostics is researched across Canada
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing diagnostics patents in Canada
Canada diagnostics patent filing is cooling — 51 filings from 36 assignees (2016–2025), led by FIO, Invidx, Chromedx; annual filings 4→2.
- FIO29
- Invidx19
- Chromedx12
- Macleod Jason Andrew7
- Nemeth Attila Csaba7
- Collier Gordon Bruce7
- Dicke William Charles7
- I STAT5
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.